Background Infliximab, a monoclonal antibody against tumor necrosis factor, is an effective
maintenance therapy for patients with Crohn's disease without fistulas. It is not known …

… Kim MS, Lee KY, Chey WY. Plasma secretin concentrations in fasting and postprandial …
You CH, Rominger JM, Chey WY. Potentiation effects of cholecystokinin octapeptide on …

OBJECTIVES: Although colon dysmotility is recognized as a pathophysiological factor in
irritable bowel syndrome (IBS), it has not been characterized. We have investigated motility …

… 74 You CH, Chey WY: Atropine abolishes the potentiation effect of secretin and
cholecystokinin-octapeptide on exocrine pancreatic secretion in humans. Pancreas 1988;3:99–103. …

Background Irritable bowel syndrome (IBS) is a common gastrointestinal disorder seen in
primary care practice. The symptoms of IBS, including abdominal pain, discomfort, and …

Background & Aims : An attenuated form of familial adenomatous polyposis has been described,
but the phenotype remains poorly understood.Methods : We performed genetic testing …

Background and aims: To evaluate the safety and efficacy of the intercellular adhesion
molecule 1 (ICAM-1) antisense phosphorothioate oligonucleotide alicaforsen (ISIS 2302) in …

Objectives: Among patients with peptic ulcer disease, the prevalence of Helicobacter pylori
has been reported to range from 80% to 90%. Thus empirical cost-effective therapy has been …

* William B. and Sheila Konar Center for Digestive and Liver Diseases and‡ Departments of
Medicine and Pathology, University of Rochester Medical Center, Rochester, New York; and …

This review describes the history of secretin discovery, identification, purification, and structural
determination; cloning of secretin and its receptor; synthetic secretin; and highly specific …